Case Report
Copyright ©The Author(s) 2021.
World J Hepatol. Mar 27, 2021; 13(3): 384-392
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.384
Figure 1
Figure 1 Images of hepatocellular carcinoma with portal vein tumour thrombus before lenvatinib treatment. A: Computed tomography image. An arrow indicates portal vein tumour thrombus; B: Three-dimensional image. The yellow mass demonstrates a viable portal vein tumour thrombus, extending to the contralateral third portal branch.
Figure 2
Figure 2 Images of hepatocellular carcinoma with portal vein tumour thrombus after lenvatinib treatment. A: Computed tomography image two weeks after the treatment. The portal vein tumour thrombus (PVTT) showed regression with partial disappearance of contrast enhancement; B: Computed tomography image three months after the treatment; C: Three-dimensional image three months after the treatment. The PVTT regressed to the contralateral first-order branch with loss of contrast enhancement. Arrows indicate PVTT.
Figure 3
Figure 3 Portal vein tumour thrombus thrombectomy. A: The right and the main portal veins were clamped by Satinsky forceps. Venotomy was placed at the bifurcation of the left portal vein; B: The portal vein tumour thrombus was thrombectomized; C: The left portal vein stump was closed by 6-0 proline.
Figure 4
Figure 4 Macroscopic and microscopic findings of the main tumour and the portal vein tumour thrombus. A: A white to brownish nodule was found in the left portal vein (arrows). Inlet: close-up picture of the removed portal vein tumour thrombus; B: The primary lesion showed severe fibrotic change with haemosiderin deposition. In the fibrosis, the viable tumour cell nests (arrow) and the necrotic tumour lesions (arrowhead) were scattered; C: High magnification demonstrated moderately to poorly differentiated tumour cells; D: Most of the portal vein tumour thrombus showed necrotic changes.